Data / Research funding / Texas / 7 Hills Pharma, LLC
7 Hills Pharma, LLC: 6 NIH awards ($9.1M), fiscal years 2021 to 2026
7 Hills Pharma, LLC in Houston, TX is funded under 6 NIH awards ($9.1M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- CJJ6DE7APKY6
- State
- Texas
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,034 | July 14, 2022 | June 30, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | NIH | National Cancer Institute | 2023 to 2024 | $1,998,400 | September 19, 2023 | August 31, 2025 | MARATHI, UPENDRA | reporter.nih.gov |
| 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,881,701 | April 26, 2023 | March 31, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors | NIH | National Cancer Institute | 2021 | $1,015,591 | September 11, 2020 | August 31, 2022 | MARATHI, UPENDRA | reporter.nih.gov |
| A small molecule integrin activator to enhance cord blood transplant | NIH | National Heart, Lung, and Blood Institute | 2021 | $928,941 | September 1, 2016 | February 28, 2023 | VANDERSLICE, PETER | reporter.nih.gov |
| Integrin Activation to Augment SARS-CoV-2 Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $297,724 | May 1, 2021 | October 31, 2022 | MARATHI, UPENDRA | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2024 | 3 | $2,950,544 | 0 | $0 |
| 2023 | 3 | $2,925,291 | 0 | $0 |
| 2022 | 1 | $999,300 | 0 | $0 |
| 2021 | 3 | $2,242,256 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 3 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 3 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 3 awards here |
Topics of its NIH awards
- Cancer
- Orphan Drug
- Rare Diseases
- Immunization
- Infectious Diseases
- Prevention
- Vaccine Related
- Immunotherapy
- Aging
- Biotechnology
- Emerging Infectious Diseases
- Lung
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.